Overview

Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety

Status:
Terminated

Trial end date:
2011-01-01

Target enrollment:

Participant gender:

Summary

As sitaxsentan is the agent most highly selective for ETA (Endothelin Type A (receptor)), and does not significantly impact sildenafil pharmacokinetics the combination of most promise for pulmonary arterial hypertension (PAH) therapy is these two oral drugs administered in combination.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Endothelin Receptor Antagonists
Sildenafil Citrate
Sitaxsentan